vs
Crane NXT, Co.（CXT）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Crane NXT, Co.的季度营收约是Orthofix Medical Inc.的1.8倍（$387.7M vs $219.9M），Crane NXT, Co.净利率更高（1.7% vs -1.0%，领先2.7%），Crane NXT, Co.同比增速更快（17.4% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-24.1M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.3%）
Crane NXT是一家总部位于美国康涅狄格州斯坦福德的工业产品企业，由理查德·特勒·克莱恩于1855年创立。曾是美国头部卫浴配件制造商，1990年出售卫浴业务后，自1960年起逐步转型为多元化控股集团，目前核心业务涵盖航空航天与电子、工程材料、流体处理、控制设备四大板块，服务化工等多个行业领域。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CXT vs OFIX — 直观对比
营收规模更大
CXT
是对方的1.8倍
$219.9M
营收增速更快
CXT
高出15.4%
2.0%
净利率更高
CXT
高出2.7%
-1.0%
自由现金流更多
OFIX
多$40.9M
$-24.1M
两年增速更快
OFIX
近两年复合增速
2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $387.7M | $219.9M |
| 净利润 | $6.4M | $-2.2M |
| 毛利率 | 40.2% | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 1.7% | -1.0% |
| 营收同比 | 17.4% | 2.0% |
| 净利润同比 | -70.5% | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXTOFIX
| Q1 26 | $387.7M | — | ||
| Q4 25 | $476.9M | $219.9M | ||
| Q3 25 | $445.1M | $205.6M | ||
| Q2 25 | $404.4M | $203.1M | ||
| Q1 25 | $330.3M | $193.6M | ||
| Q4 24 | $399.1M | $215.7M | ||
| Q3 24 | $403.5M | $196.6M | ||
| Q2 24 | $370.6M | $198.6M |
净利润CXTOFIX
| Q1 26 | $6.4M | — | ||
| Q4 25 | $47.5M | $-2.2M | ||
| Q3 25 | $50.5M | $-22.8M | ||
| Q2 25 | $24.9M | $-14.1M | ||
| Q1 25 | $21.7M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $47.1M | $-27.4M | ||
| Q2 24 | $41.6M | $-33.4M |
毛利率CXTOFIX
| Q1 26 | 40.2% | — | ||
| Q4 25 | 42.4% | 71.1% | ||
| Q3 25 | 43.3% | 72.2% | ||
| Q2 25 | 41.7% | 68.7% | ||
| Q1 25 | 42.4% | 62.8% | ||
| Q4 24 | 45.2% | 69.0% | ||
| Q3 24 | 42.5% | 68.7% | ||
| Q2 24 | 43.4% | 67.8% |
营业利润率CXTOFIX
| Q1 26 | — | — | ||
| Q4 25 | 16.7% | 0.2% | ||
| Q3 25 | 18.4% | -8.3% | ||
| Q2 25 | 11.8% | -7.9% | ||
| Q1 25 | 11.3% | -25.2% | ||
| Q4 24 | 17.7% | -5.3% | ||
| Q3 24 | 18.6% | -9.6% | ||
| Q2 24 | 18.2% | -12.5% |
净利率CXTOFIX
| Q1 26 | 1.7% | — | ||
| Q4 25 | 10.0% | -1.0% | ||
| Q3 25 | 11.3% | -11.1% | ||
| Q2 25 | 6.2% | -6.9% | ||
| Q1 25 | 6.6% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 11.7% | -13.9% | ||
| Q2 24 | 11.2% | -16.8% |
每股收益（稀释后）CXTOFIX
| Q1 26 | — | — | ||
| Q4 25 | $0.82 | $-0.05 | ||
| Q3 25 | $0.87 | $-0.57 | ||
| Q2 25 | $0.43 | $-0.36 | ||
| Q1 25 | $0.38 | $-1.35 | ||
| Q4 24 | $1.00 | $-0.76 | ||
| Q3 24 | $0.81 | $-0.71 | ||
| Q2 24 | $0.72 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $228.3M | $82.0M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $1.2B | $450.0M |
| 总资产 | $3.6B | $850.6M |
| 负债/权益比越低杠杆越低 | 1.22× | — |
8季度趋势，按日历期对齐
现金及短期投资CXTOFIX
| Q1 26 | $228.3M | — | ||
| Q4 25 | $233.8M | $82.0M | ||
| Q3 25 | $182.4M | $62.9M | ||
| Q2 25 | $152.5M | $65.6M | ||
| Q1 25 | $173.8M | $58.0M | ||
| Q4 24 | $165.8M | $83.2M | ||
| Q3 24 | $165.1M | $30.1M | ||
| Q2 24 | $175.5M | $26.4M |
总债务CXTOFIX
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $834.3M | $157.2M | ||
| Q2 25 | $861.8M | $157.0M | ||
| Q1 25 | $541.1M | $156.9M | ||
| Q4 24 | $540.6M | $157.0M | ||
| Q3 24 | $638.2M | $118.5M | ||
| Q2 24 | $638.9M | $118.0M |
股东权益CXTOFIX
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $450.0M | ||
| Q3 25 | $1.2B | $442.5M | ||
| Q2 25 | $1.2B | $458.3M | ||
| Q1 25 | $1.1B | $458.3M | ||
| Q4 24 | $1.1B | $503.1M | ||
| Q3 24 | $1.1B | $525.9M | ||
| Q2 24 | $989.8M | $546.0M |
总资产CXTOFIX
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.1B | $850.6M | ||
| Q3 25 | $2.9B | $832.6M | ||
| Q2 25 | $2.9B | $837.2M | ||
| Q1 25 | $2.4B | $823.1M | ||
| Q4 24 | $2.4B | $893.3M | ||
| Q3 24 | $2.4B | $867.9M | ||
| Q2 24 | $2.4B | $882.0M |
负债/权益比CXTOFIX
| Q1 26 | 1.22× | — | ||
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.69× | 0.36× | ||
| Q2 25 | 0.73× | 0.34× | ||
| Q1 25 | 0.49× | 0.34× | ||
| Q4 24 | 0.51× | 0.31× | ||
| Q3 24 | 0.60× | 0.23× | ||
| Q2 24 | 0.65× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-24.1M | $16.8M |
| 自由现金流率自由现金流/营收 | -6.2% | 7.6% |
| 资本支出强度资本支出/营收 | 2.6% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CXTOFIX
| Q1 26 | — | — | ||
| Q4 25 | $105.8M | $27.7M | ||
| Q3 25 | $92.0M | $12.4M | ||
| Q2 25 | $62.8M | $11.6M | ||
| Q1 25 | $-19.1M | $-18.4M | ||
| Q4 24 | $81.1M | $23.7M | ||
| Q3 24 | $66.7M | $11.7M | ||
| Q2 24 | $56.8M | $9.0M |
自由现金流CXTOFIX
| Q1 26 | $-24.1M | — | ||
| Q4 25 | — | $16.8M | ||
| Q3 25 | $78.7M | $2.5M | ||
| Q2 25 | $55.8M | $4.5M | ||
| Q1 25 | $-32.2M | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | $53.5M | $6.3M | ||
| Q2 24 | $47.9M | $-360.0K |
自由现金流率CXTOFIX
| Q1 26 | -6.2% | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | 17.7% | 1.2% | ||
| Q2 25 | 13.8% | 2.2% | ||
| Q1 25 | -9.7% | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | 13.3% | 3.2% | ||
| Q2 24 | 12.9% | -0.2% |
资本支出强度CXTOFIX
| Q1 26 | 2.6% | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | 3.0% | 4.8% | ||
| Q2 25 | 1.7% | 3.5% | ||
| Q1 25 | 4.0% | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | 3.3% | 2.7% | ||
| Q2 24 | 2.4% | 4.7% |
现金转化率CXTOFIX
| Q1 26 | — | — | ||
| Q4 25 | 2.23× | — | ||
| Q3 25 | 1.82× | — | ||
| Q2 25 | 2.52× | — | ||
| Q1 25 | -0.88× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.42× | — | ||
| Q2 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXT
| Detection and Traceability Technologies | $194.9M | 50% |
| Security and Authentication Technologies | $192.8M | 50% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
